Multiple Myeloma

P4, N=3800, Recruiting, Abramson Cancer Center at Penn Medicine | Phase classification: P=N/A --> P4

P2, N=24, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

This case highlights the importance of considering plasma cell neoplasm in the differential diagnosis of multicentric destructive calvarial masses. It illustrates the potential role of staged surgical resection in selected patients with giant calvarial involvement.

These findings provide an exploratory description of PD-1/PD-L1 expression patterns within the BM microenvironment in MM. Only in advanced cases according to ISS, PD-L1 expression on PC was linked to BM T cells frequency. PD-1/PD-L1 expression patterns were not linked to treatment response.

Importantly, co-administration of ruxolitinib, a clinically approved JAK1/2 inhibitor, dampened IFN-β signaling and rescued mice from lethal toxicity. Collectively, these findings define the pathophysiological consequences of sustained systemic IFN-β exposure and identify ruxolitinib as a potential mitigation strategy to manage IFN-β-mediated toxicity during OV treatment.

P1/2, N=35, Not yet recruiting, Odense University Hospital

P1, N=97, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.

P=N/A, N=198, Not yet recruiting, Wuerzburg University Hospital

P1, N=8, Terminated, Second Affiliated Hospital of Xi'an Jiaotong University | N=34 --> 8 | Not yet recruiting --> Terminated; Achieved the proof of concept

P=N/A, N=120, Suspended, Ohio State University Comprehensive Cancer Center | Recruiting --> Suspended

P3, N=1226, Not yet recruiting, University of Leeds

P1, N=35, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed